Skip to main content
. 2016 Nov 7;7(52):85917–85928. doi: 10.18632/oncotarget.13185

Figure 3. Combined treatment of gefitinib and Dex inhibited cell death in the PC9-xenograft mouse model.

Figure 3

(A) SCID mice were inoculated with PC9 (EGFRexon19del E746-A750) cells (5 × 106) subcutaneously at the abdominal site. When tumor volumes reached 800 mm3, the vehicle control, gefitinib (Gefi: p.o. 20 mg/kg) alone or in combinations with Dex (p.o. 0.07 mg/kg or 0.35 mg/kg) were orally administered every day for a total of 10 days. Data are means ± SEM. (n = 4). **p < 0.01 and ***p < 0.001 compared to VC; #p < 0.05. (B) After drug exposure for 3 days, tumor cell apoptosis was characterized by cytoplasmic shrinkage and nuclear chromatin condensation in H&E staining and were positive for cleaved caspase 3 positive cells (shown as brown). Scale bars, 50 μm. cc-3, cleaved caspase 3.